Considering that interleukin 10 (IL10), transforming growth factor beta1 (TGFB1), and interferon gamma (IFNG) are involved in the susceptibility of BeWo trophoblast cells to Toxoplasma gondii infection, the aim of the present study was to investigate the effector mechanisms triggered by these cytokines in the control of T. gondii in BeWo cells. For this purpose, infected/uninfected BeWo cells were treated with IL10, TGFB1 (50 ng/ml), and IFNG (20 or 100 ng/ml) in order to verify the phosphorylation of signal transducers and activators of transcription 1 (STAT1), STAT3, and Smad2, parasite intracellular proliferation, as well as the Th1/Th2/IL17A cytokine production. The treatment of BeWo cells with IL10 and TGFB1 favored T. gondii proliferation, and these findings were associated with STAT3 and Smad2 phosphorylation, respectively (P , 0.05). Also, these cytokine treatments were able to down-modulate TNF alpha (TNFA) and IL6 production (P , 0.05). Low concentration of IFNG was unable to control T. gondii infection but was able to trigger STAT1 phosphorylation and up-regulate IL6 and IL17A production; whereas a high concentration of IFNG was unable to activate STAT1 but down-modulated IL6 and TNFA and increased T. gondii proliferation (P , 0.05). IL10, TGFB1, and IFNG regulate a differential T. gondii proliferation in BeWo cells because they distinctly trigger intracellular signaling pathways and cytokine production, especially IL6 and TNFA. Our data open new windows to understand the mechanisms triggered by IL10, TGFB1, and IFNG at the maternal-fetal interface in the presence of T. gondii, contributing to recognizing the importance of these effector mechanisms involved in the vertical transmission of this parasite.
INTRODUCTION
Toxoplasma gondii is an intracellular protozoan parasite that infects a wide range of warm-blooded vertebrates, including humans [1, 2] . During congenital infection in humans, severe manifestations can be observed, such as retinochoroiditis and miscarriage [3, 4] , characterizing an important public health problem in many countries, including Brazil [5, 6] .
A Th1-type immune response against T. gondii is observed during infection, with the participation of interferon gamma (IFNG) and other proinflammatory cytokines [7] [8] [9] [10] . On the other hand, a normal pregnancy is characterized by a preferential Th2-type immune response and T regulatory cell responses [11] , with the production of anti-inflammatory cytokines such as interleukin 10 (IL10) and transforming growth factor beta1 (TGFB1) by both maternal and fetal cells, including trophoblast cells [12, 13] . The role of trophoblast cells in the immunology of pregnancy, especially in the presence of intracellular pathogens such as T. gondii and Neospora caninum, has been studied by our group using wellestablished cell lines, such as BeWo cells [14] [15] [16] [17] [18] [19] . These cells were isolated from a human choriocarcinoma [20] and preserved their trophoblastic characteristics, such as hormone production and cytokine release under in vitro stimulation [21, 22] . Even though BeWo cells are derived from a choriocarcinoma, they are becoming an excellent in vitro model to investigate T. gondii infection in trophoblast cells. In fact, our group has investigated several aspects of the immunology of pregnancy using these cells as a trophoblast model, including their cross-talk with monocytes [18] and the role of cytokines and drugs during T. gondii infection [14, 15, 17, 19] .
Our previous study verified that BeWo cells are highly susceptible to T. gondii infection when stimulated with IL10 and TGFB1 [15] . Interestingly, we verified that IFNG was unable to control T. gondii infection in BeWo cells [14] or significantly increased the infectivity in these cells [15] , although this cytokine is the major molecule involved in the immune response against this parasite [8, 10] . Thus, it is possible to assume that BeWo trophoblast cells are resistant to the proinflammatory effects of IFNG, probably in order to maintain the development of the embryo in vivo and to avoid rejection during pregnancy, which could favor T. gondii infection in the placental tissues [14, 15] . IL10, TGFB1, and IFNG trigger different intracellular signaling pathways [23] . IL10 and IFNG bind to specific receptors in the plasma membrane, triggering the cytoplasmic Janus kinases (JAK) that are coupled to these receptors, which, in turn, phosphorylate signal transducers and the activation of transcription 3 (STAT3) or STAT1, promoting an antiinflammatory or proinflammatory response, respectively [24] [25] [26] [27] [28] . IL10 and IFNG receptors have been found in human trophoblast [29] and BeWo cells [30] , although reduced STAT1 phosphorylation has been observed in human trophoblast cells [31] . On the other hand, TGFB1 binds to its receptors in the plasma membrane and triggers Sma-and Madrelated (Smad) proteins (Smad2 and Smad3) that regulate antiinflammatory proteins [32] [33] [34] [35] . TGFB has been detected in human term placenta [36] , and BeWo cells are able to secrete this cytokine [15, 16] .
Given that IL10, TGFB1, and IFNG are involved in the increased susceptibility of BeWo trophoblast cells to T. gondii infection [15] , the aim of the present study was to investigate the effector mechanisms triggered by these cytokines, including intracellular signaling pathways upon release, which could act in the T. gondii proliferation process in a human trophoblast model. Studies in human trophoblast cells have demonstrated the intracellular mechanisms potentially interfering in the control of T. gondii infection. However, further data are necessary to understand the role of critical cytokines in hostparasite interactions, particularly at the maternal-fetal interface, in order to contribute to the development of new effective drugs to prevent congenital toxoplasmosis.
MATERIALS AND METHODS

Ethics Statement, Cell Culture, and Parasites
The present research protocol was submitted to and approved by the Ethics Committee of the Federal University of Uberlandia, MG, Brazil (protocol number 197/08). The BeWo cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained in 75-cm 2 culture flasks in Roswell Park Memorial Institute (RPMI) 1640 medium (Cultilab, Campinas, SP, Brazil) supplemented with 100 units/ml penicillin, 100 lg/ml streptomycin (Sigma Chemical Co., St. Louis, MO), and 10% heat-inactivated fetal bovine serum (FBS) (Cultilab) in a humidified incubator at 378C and 5% CO 2 [19] .
Tachyzoites of the T. gondii 2F1 strain, which constitutively express cytoplasmic beta-galactosidase and are derived from the highly virulent RH strain, were a gift from Dr. Vern Carruthers (Medical School of Michigan University). The parasites were propagated in BeWo cells maintained in RPMI 1640 medium supplemented with penicillin, streptomycin, and 2% FBS at 378C and 5% CO 2 [19] .
T. gondii Infection in BeWo Cells Treated with IL10, TGFB1, or IFNG
In the first set of experiments, BeWo cells were cultured in 6-well plates (1 3 10 6 cells/well/ml) in RPMI 1640 medium with 10% FBS, at 378C in 5% CO 2 , and after 24 h, the cells were treated as follows: 1) stimulated with recombinant cytokines, rIL10 or rTGFB1 (R&D Systems, Minneapolis, MN), at 50 ng/ml [15] for 1, 3, 6, and 24 h in RPMI 1640 medium with 2% FBS; 2) infected by T. gondii at the proportion of five parasites per cell (5:1) for 1, 3, 6, and 24 h in RPMI 1640 medium with 2% FBS; or 3) infected by T. gondii (5:1) in RPMI 1640 medium with 2% FBS, washed with medium after 3 h to remove extracellular parasites, and then treated with rIL10 or rTGFB1 (50 ng/ml) for 1, 3, 6, and 24 h in RPMI 1640 medium with 2% FBS, according to previous studies [37, 38] . Uninfected and untreated cells were used as controls and maintained in RPMI 1640 medium with 2% FBS. Next, cells were harvested, centrifuged at 400 3 g for 5 min and lysed on ice with lysis buffer (50 mM TrisHCl, pH 8.0, 0.1 mM ethylenediaminetetraacetic acid, 0.5% Triton X-100, 10% glycerol, 1 mM dithiothreitol, and 200 mM NaCl) supplemented with a protease inhibitor cocktail (Complete; Roche Diagnostic, Mannheim, Germany), 1 mM sodium orthovanadate (Na 3 VO 4 ) and sodium fluoride (NaF) (both from Sigma) and submitted to three freeze-thaw cycles [19] . After centrifugation at 15 000 3 g for 15 min at 48C, the supernatants were collected, the concentration of total protein was measured using the Bradford assay [39] , and the samples were submitted to Western blot analysis.
In a second set of experiments, T. gondii proliferation in BeWo cells treated with several concentrations of rIFNG was analyzed because our previous studies demonstrated differential infectivity of these cells in the presence of this cytokine [14, 15] . For this purpose, BeWo cells were cultured in 96-well plates (2 3 10 4 cells/well/200 ll) in RPMI 1640 medium with 10% FBS at 378C and 5% CO 2 for 24 h. Next, cells were infected with T. gondii tachyzoites (5:1) in RPMI 1640 medium with 2% FBS, and, after 3 h, cells were washed to remove extracellular parasites and treated with increasing concentrations (20, 50 , 100, 150, and 200 ng/ml) of rIFNG (Invitrogen Life Technologies, Carlsbad, CA) for an additional 24 h in RPMI 1640 medium with 2% FBS. Cells were analyzed for T. gondii intracellular proliferation using a colorimetric betagalactosidase assay as previously described [19] . T. gondii intracellular proliferation data were expressed as the number of tachyzoites calculated in relation to the reference curve of 2F1 strain tachyzoites, ranging from 1 3 10 6 to 15.625 3 10 3 parasites. In a third set of experiments, the intracellular signaling pathway dependent on STAT1 was verified in BeWo cells treated with rIFNG. BeWo cells were cultured in 6-well plates (1 3 10 6 cells/well/ml) as described above and treated as follows: 1) infected by T. gondii (5:1) for 1, 6, and 24 h in RPMI 1640 medium with 2% FBS; 2) treated with rIFNG at 20 or 100 ng/ml for 1, 6, and 24 h in RPMI 1640 medium with 2% FBS; or 3) infected by T. gondii (5:1), washed with RPMI medium after 3 h to remove extracellular parasites, and treated with rIFNG at 20 or 100 ng/ml for 1, 6, and 24 h in RPMI 1640 medium with 2% FBS [31] . Uninfected and untreated cells were used as controls and maintained in RPMI 1640 medium with 2% FBS. Next, cells were harvested and analyzed as described above for the first set of experiments.
Western Blot Analysis for Phosphorylated Proteins
Total protein samples (60 lg) were subjected to polyacrylamide gel electrophoresis under denaturing conditions (SDS-PAGE at 8% or 12%), and the proteins were electrotransferred to polyvinylidene fluoride membranes (Thermo Scientific, Rockford, IL). Blotted membranes were blocked with 4% skimmed milk in Tris-buffered saline solution (TBS, TRIS 25 mM and NaCl 0.15 M, pH 7.4) for 1 h at room temperature and incubated overnight with the following primary antibodies: mouse monoclonal anti-phosphoSTAT3 (Tyr 705 ) (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA) or mouse monoclonal anti-total STAT3 (1:500; R&D Systems); rabbit polyclonal anti-phosphoSmad2 (S 465/467 ) (1:1000; Millipore, São Paulo, SP, Brazil) or mouse monoclonal antitotal Smad2/3 (1:1000; Santa Cruz Biotechnology); rabbit polyclonal antiphosphoSTAT1 (Tyr 701 ) (1:1000; R&D Systems) or mouse monoclonal antitotal STAT1 (1:500; Invitrogen); or mouse monoclonal anti-beta-actin (1:1000; Santa Cruz Biotechnology) in TBS with 2% skimmed milk. Next, the membranes were incubated with the respective peroxidase-labeled secondary antibodies (1:3000; Jackson ImmunoResearch Laboratories, West Grove, PA) in TBS with 2% skimmed milk for 2 h at room temperature. The reaction was revealed by chemiluminescence (ECL SuperSignal kit; Thermo Scientific) and equal loading of the proteins was confirmed by staining the blots with 1% Ponceau solution. Densitometric analyses were performed using the KODAK software (1D Image Analysis Software 3.5) in order to determine the mean intensity of the bands [19] . The data were expressed as relative density of the ratio between the phosphorylated protein and beta-actin bands.
T. gondii Infection in BeWo Cells Treated with STAT3, Smad2, or STAT1 Inhibitors First, the cytotoxicity of STAT3, Smad2, or STAT1 inhibitors in BeWo cells was verified. Cells were seeded in 96-well plates (1 3 10 5 cells/well/200 ll) for 24 h and treated or not with increasing concentrations (0.1-10 lM) of STAT3 (WP1066, Santa Cruz Biotechnology), Smad2 (SB431542, Sigma) or STAT1 (Fludarabine, Sigma) inhibitors in RPMI 1640 medium with 10% FBS at 378C in 5% CO 2 for an additional 24 h. Cell viability was evaluated using the tetrazolium salt colorimetric (MTT) assay as previously described [40] . The data were analyzed as percentage of viable cells in comparison to untreated cells (100% of cell viability).
Next, the BeWo cells were cultured in 96-well plates (2 3 10 4 cells/well/ 200 ll) for 24 h, pretreated with WP1066 (0.1-0.5 lM), SB431542 (2.5-10 lM), or Fludarabine (0.1-0.5 lM) for 2 h and incubated with tachyzoites of T.
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gondii (5:1) for 3 h. Cells were washed to remove extracellular parasites and again treated with WP1066, SB431542, or Fludarabine in the presence or absence of rIL10 (50 ng/ml), rTGFB1 (50 ng/ml), or rIFNG (20 ng/ml) for an additional 24 h, respectively. Infected and untreated cells or infected and cytokine-treated cells were used as controls. In parallel, uninfected BeWo cells were only treated with rIL10 (50 ng/ml), rTGFB1 (50 ng/ml), or rIFNG (20 ng/ ml) for 24 h. Untreated and uninfected cells were used as controls. Finally, the cell-free supernatants were collected and stored at À808C for the subsequent analysis of cytokines by cytometric bead array (CBA). T. gondii-infected cells were analyzed for parasite intracellular proliferation by beta-galactosidase assay as previously described [19] . In a set of parallel experiments, BeWo cells (2 3 10 4 cells/well/200 ll in 96-well plates), infected or not by T. gondii, were treated with 100 ng/ml rIFNG for 24 h; the cell-free supernatants were collected for the posterior measurement of cytokines by CBA.
Measurement of Th1, Th2, and IL17A Cytokines by CBA Human cytokines (IL2, IFNG, tumor necrosis factor alpha [TNFA], IL6, IL4, IL10, and IL17A) were measured in supernatants of BeWo cells using the Th1/Th2/Th17 kit (BD Bioscience, San Jose, CA) by CBA according to the manufacturer's instructions. Samples were analyzed under BD flow cytometry (FACSCalibur; BD Company, San Diego, CA), and data were recorded using specialized BD Cell Quest software and CBA software. The results were expressed as mean fluorescence intensity (MFI) [17, 19, 41] .
T. gondii Intracellular Proliferation in BeWo Cells Treated with IL6 or TNFA
BeWo cells were cultured in 96-well plates (2 3 10 4 cells/well/200 ll) for 24 h and primed or not with rTNFA (Millipore) or rIL6 (R&D Systems) at concentrations ranging from 100 to 500 pg/ml for an additional 24 h. Cells were infected by T. gondii (5:1) for 3 h, treated again with rTNFA or rIL6 for an additional 24 h, and analyzed for parasite proliferation using the colorimetric beta-galactosidase assay as previously described [19] .
Statistical Analysis
All the data were expressed as mean 6 SEM of three independent experiments performed in triplicate. Differences among groups were assessed by one-way ANOVA with the Bonferroni multiple comparison post hoc test using GraphPad Prism version 4.0 software (GraphPad Software, Inc., San Diego, CA) being considered significant when P , 0.05.
RESULTS
Treatment of BeWo Cells with IL10 and TGFB1 UpRegulates T. gondii Infection in a STAT3-and Smad2-Dependent Manner, Respectively
The intracellular signaling pathways activated by IL10 and TGFB1 in BeWo cells infected by T. gondii, which could be involved in the control of parasite proliferation, were investigated ( Fig. 1A-F In order to confirm these findings, experiments were performed using the inhibitors of these intracellular pathways. First, the concentration of inhibitors that did not alter the cell viability was determined. The MTT analyses demonstrated no change in cell viability when BeWo cells were treated with STAT3 (WP1066) or Smad2 (SB431542) inhibitors, except for 10 lM WP1066 (data not shown). Thus, concentrations ranging from 0.1 to 0.5 lM for WP1066 and 2.5 to 10 lM for SB431542 were selected in further experiments.
BeWo cells treated with rIL10 or rTGFB1 showed increased T. gondii proliferation in comparison with untreated cells (P , 0.05; Fig. 1 , C and F). However, the parasite proliferation decreased significantly when BeWo cells were treated with WP1066 or SB431542 inhibitors in the presence or absence of rIL10 or rTGFB1 when compared with untreated or cytokinetreated cells (P , 0.05; Fig. 1 , C and F).
Absence of STAT1 Phosphorylation Is Associated with Increased T. gondii Intracellular Proliferation in BeWo Cells
Our previous studies demonstrated that IFNG was unable to control T. gondii infection [14] or significantly increased the infectivity in BeWo cells [15] . To further understand this phenomenon, experiments were carried out to establish the concentrations of IFNG that cause these effects in infected BeWo cells. The treatment of BeWo cells with 20 ng/ml rIFNG did not control the parasite proliferation when compared to untreated cells ( Fig. 2A) . Moreover, increased T. gondii proliferation was detected in BeWo cells treated with rIFNG (50-200 ng/ml) in comparison to untreated cells (P , 0.05; Fig. 2A) . Thus, the concentrations of 20 and 100 ng/ml were chosen to verify the STAT1 phosphorylation.
STAT1 phosphorylation was detected in uninfected BeWo cells after treatment with 20 ng/ml rIFNG for 1, 6, and 24 h, although this phosphorylation was significant only after 6 h of treatment (P , 0.05; Fig. 2 , B and C). Under T. gondii infection, however, STAT1 phosphorylation increased after rIFNG treatment when compared to untreated cells or respective controls in the absence of infection (P , 0.05; Fig. 2 , B and C) at all of the time points analyzed. Furthermore, STAT1 phosphorylation was not observed in untreated and infected cells (Fig. 2, B and C) . On the other hand, no STAT1 phosphorylation was detected in uninfected or infected BeWo cells after treatment with 100 ng/ml rIFNG at any time (Fig.  2D) .
In order to confirm the effect of STAT1 in the control of parasite proliferation, we performed experiments using the STAT1 inhibitor (Fludarabine) in the presence or absence of 20 ng/ml rIFNG because only this concentration was able to trigger STAT1 phosphorylation in BeWo cells. We first determined the concentration of the inhibitor that did not alter cell viability. The MTT analyses demonstrated decreased cell viability after the treatment of BeWo cells with 5 and 10 lM Fludarabine when compared to untreated cells (data not shown). Fludarabine concentrations ranging from 0.1 to 0.5 lM were selected for use in further experiments. As previously observed, BeWo cells treated with 20 ng/ml rIFNG were not able to control T. gondii proliferation in relation to untreated cells (Fig. 2E ), but when treated with 0.1-0.5 lM Fludarabine in the absence or presence of rIFNG (20 ng/ml), the parasite proliferation increased in comparison with untreated or only rIFNG-treated cells, respectively (P , 0.05; Fig. 2E ). To verify the effect of IL10 and TGFB1 on the production of Th1/Th2/IL17A cytokines in BeWo cells infected or not by T. gondii, the levels of cytokines in cell-free supernatants were measured using the CBA assay (Fig. 3A-D) . When BeWo cells were infected by T. gondii but not treated with rIL10 or rTGFB1, a significant production of IL6 (Fig. 3A) and IL17A ( Fig. 3C) (P , 0.05) was verified, while no change in TNFA (Fig. 3B) or IL10 (Fig. 3D ) release was detected in the supernatant in comparison with untreated and uninfected cells (medium).
Treatment with rIL10 in uninfected cells reduced the levels of IL6 in relation to untreated and uninfected cells (medium) (P , 0.05; Fig. 3A ). In the presence of infection, rIL10-treated cells showed higher IL6 secretion when compared to untreated and uninfected cells (medium) (P , 0.05), but the IL6 release decreased in comparison to untreated and infected cells (P , 0.05; Fig. 3A ). When the STAT3 inhibitor (WP1066) was added in the presence of rIL10, IL6 levels were reduced in infected BeWo cells in comparison to untreated and uninfected cells (medium) or to the respective controls in the absence of the inhibitor (P , 0.05; Fig. 3A) . Likewise, rIL10-treated and infected cells demonstrated reduced TNFA production in comparison to untreated and uninfected cells (medium) or only infected cells (P , 0.05; Fig. 3B ), and the WP1066 treatment promoted an up-regulation of TNFA release when compared to untreated and uninfected cells (medium) or to the respective controls in the absence of the inhibitor, regardless of infection (P , 0.05; Fig. 3B ). Increased IL17A production in BeWo cells was detected in the presence of rIL10 and T. gondii when compared to untreated and uninfected cells (medium) (P , 0.05; Fig. 3C ). Moreover, IL17A levels were reduced in infected BeWo cells treated with WP1066 when compared to untreated and uninfected cells (medium) or to the respective controls in the absence of the inhibitor (P , 0.05; Fig. 3C ). IL10 was not determined in the supernatant of BeWo cells treated with rIL10 (Fig. 3D) .
At the same time, when BeWo cells were treated with rTGFB1, reduced levels of IL6 were observed regardless of infection in comparison to untreated and uninfected cells (medium) or only infected cells (P , 0.05; Fig. 3A) , while increased IL17A secretion was detected in infected cells in relation to untreated cells and uninfected cells (medium) (P , 0.05; Fig. 3C ). In the presence of rTGFB1 and its Smad2 inhibitor (SB431542), up-regulation of IL6 was verified when compared to untreated and uninfected cells (medium) or to the respective controls in the absence of the inhibitor, regardless of infection (P , 0.05; Fig. 3A ), but rTGFB1 plus SB431542 did not alter the IL17 release in relation to any experimental (Fig. 3C) . No change in TNFA (Fig. 3B) or IL10 (Fig. 3D ) production was observed in uninfected or infected BeWo cells treated with rTGFB1 and/or Smad2 inhibitor (SB431542) in relation to untreated and uninfected cells (medium) or to the respective controls in the absence of the inhibitor. IL2, IFNG, and IL4 production were not observed in BeWo cells under any experimental conditions. The IL6 and TNFA Production in BeWo Cells Is DoseDependent on IFNG and, Consequently, on STAT1 Phosphorylation
To verify the effect of different concentrations of IFNG on the production of Th1/Th2/IL17A cytokines in BeWo cells infected or not by T. gondii, the levels of cytokines in cell-free supernatants were measured using the CBA assay (Fig. 4A-D) . As described above, only significant levels of IL6 (Fig. 4A) and IL17A (Fig. 4C) (P , 0.05) were detected in the supernatant from untreated and infected cells in comparison with untreated and uninfected cells (medium). Likewise, uninfected or infected BeWo cells treated with 20 ng/ml rIFNG increased the levels of IL6 (Fig. 4A) and IL17A (Fig.   4C ) in comparison to untreated and uninfected cells (medium) (P , 0.05). No significant change in TNFA (Fig. 4B) and IL10 (Fig. 4D ) release was observed in BeWo cells treated with 20 ng/ml rIFNG when compared to untreated and uninfected cells (medium). In the presence of STAT1 inhibitor (Fludarabine), both infected and uninfected BeWo cells treated with 20 ng/ml rIFNG showed down-modulation of IL6 (Fig. 4A) and IL17A (Fig. 4C ) and up-regulation of IL10 (Fig. 4D ) release in relation to the respective controls in the absence of the inhibitor (P , 0.05). Also, treatment with rIFNG and Fludarabine only triggered the up-regulation of TNFA in uninfected cells when compared to untreated and uninfected cells (medium) or to the respective control in the absence of the inhibitor (P , 0.05; Fig. 4B) .
However, the treatment of BeWo cells with 100 ng/ml rIFNG reduced the levels of IL6 (Fig. 4A) and TNFA (Fig. 4B ) in the supernatants, regardless of infection, when compared to untreated and uninfected cells (medium) or to the cells treated with 20 ng/ml rIFNG (P , 0.05). No significant change in IL17A (Fig. 4C) and IL10 (Fig. 4D ) release was observed in BeWo cells treated with 100 ng/ml rIFNG when compared to
FIG. 2. Detection of STAT1 phosphorylation and T. gondii proliferation in BeWo cells (A-E)
. Cells were exposed to T. gondii, treated or not (medium) with rIFNG (20-200 ng/ml), and the number of tachyzoites (A) was determined via a colorimetric microtiter assay. Next, BeWo cells were incubated or not (medium) with rIFNG (20 or 100 ng/ml) for several times in the presence or absence of T. gondii infection. All the cells were submitted to Western blot analysis to detect STAT1 phosphorylation (phosphoSTAT1), total protein, and beta-actin. Representative Western blots for phosphoSTAT1 (B, D) and densitometric analyses (C) of the respective protein calculated from the ratio between the phosphoprotein and beta-actin bands. Also, BeWo cells were pretreated or not (medium) with Fludarabine in the presence or absence of rIFNG (20 ng/ml), and the number of tachyzoites (E) was determined via a colorimetric microtiter assay. The data were expressed as the mean 6 SEM of three independent experiments performed in triplicate. All the data were analyzed by one-way ANOVA with the Bonferroni multiple comparison post hoc test. Significant differences in comparison with medium (*P , 0.05), with the respective cytokine treatments in the absence of infection ( # P , 0.05), or with the respective cytokine treatments in the absence of the inhibitor (Fludarabine) ( & P , 0.05). 
INTRACELLULAR PATHWAYS AND T. GONDII INFECTION
IL6 and TNFA Control T. gondii Infection in BeWo Cells
In order to confirm whether TNFA and IL6 are involved in the control of T. gondii growth in BeWo cells, cells were infected and treated with these recombinant cytokines. BeWo cells treated with rTNFA or rIL6, at concentrations ranging from 100 to 500 pg/ml, showed significantly reduced parasite proliferation in comparison to untreated cells (P , 0.05; Fig. 5 , A and B).
Proposed Model of the Intracellular Mechanisms Triggered by IL10, TGFB1, and IFNG in BeWo Cells During T. gondii Infection
Based on our results, a proposed model of the effector mechanisms activated by IL10, TGFB1, and IFNG in BeWo cells infected by T. gondii is shown in Figure 6 . When BeWo cells are treated with rIL10, STAT3 phosphorylation is triggered and promotes the down-modulation of IL6 and TNFA and, consequently, an increase in the number of T. gondii tachyzoites (Fig. 6A) . In the presence of rTGFB1, Smad2 phosphorylation is triggered with the subsequent reduced IL6 production, and consequently an increased number of T. gondii tachyzoites (Fig. 6B) . Finally, when BeWo cells are treated with 20 ng/ml rIFNG (low concentration), STAT1 phosphorylation and levels of IL6 and IL17A are up-regulated with no control of parasite proliferation (Fig. 6C, left) . However, the treatment of BeWo cells with 100 ng/ml rIFNG (high concentration) does not trigger STAT1 phosphorylation with the subsequent reduction of IL6 and TNFA release, favoring T. gondii proliferation (Fig. 6C, right) .
DISCUSSION
In the present study, we investigated the effector mechanisms triggered by IL10, TGFB1, and IFNG in BeWo trophoblast cells that could explain the increased T. gondii proliferation in these cells under these cytokine treatments. For this purpose, we investigated the intracellular signaling pathways and cytokine production involved in T. gondii proliferation in this trophoblast model.
Our data demonstrated early increased STAT3 phosphorylation in BeWo cells treated with rIL10 regardless of T. gondii infection. In addition, we also verified the higher parasite proliferation in BeWo cells treated with rIL10, in agreement with our previous study [15] . When we investigated T. gondii proliferation in IL10-treated cells in the presence of STAT3 inhibitor, it was reduced to levels smaller than untreated or cells only treated with IL10. It was concluded that the higher T. gondii infectivity induced by IL10 in BeWo cells was dependent of STAT3 activation. To the best of our knowledge, the present study for the first time shows increased T. gondii infection in BeWo trophoblast cells in a manner dependent on STAT3 phosphorylation induced by IL10. Recent studies have demonstrated STAT3 phosphorylation triggered by IL10 in different experimental models in order to modulate the immune response favoring infection. STAT3 phosphorylation has been shown to be essential for the survival and proliferation of human trophoblast cells from JEG-3 lineage [42] . It has been shown that supernatants of Lactobacillus rhamnosus cultures induced STAT3 phosphorylation and IL10 production in human trophoblast cells, contributing to the immunosuppression at the maternal-fetal interface [43] . Mesenchymal stem cells from rat bone marrow down-modulated the maturation of murine dendritic cells when IL10 triggered the JAK1/STAT3 signaling pathway [44] . Furthermore, IL10 and STAT3 are involved in the increased susceptibility to infections caused by Leishmania amazonensis, Leishmania donovani, the Newcastle disease virus, and Listeria monocytogenes [45] [46] [47] [48] . According to our present data, IL10 also promoted higher infectivity during T. gondii infection in murine dendritic cells [49] , and increased IL10 levels were associated with the high susceptibility to reinfection with different recombinant T. gondii strains in BALB/c mice [50] . Thus, IL10 and STAT3 are involved in . BeWo cells were treated or not (medium) with rIL6 or rTNFA, and the number of tachyzoites was determined via a colorimetric microtiter assay. Data were expressed as the mean 6 SEM of the number of tachyzoites calculated from a reference curve and are representative of three independent experiments performed in triplicate. All the data were analyzed by one-way ANOVA with the Bonferroni multiple comparison post hoc test. Significant differences in comparison with medium (*P , 0.05).
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Similarly to the IL10 data, a previous study by our group also demonstrated that TGFB1 up-regulated T. gondii proliferation in BeWo cells [15] . Furthermore, we observed Smad2 phosphorylation induced by TGFB1 in BeWo cells, regardless of T. gondii. The number of tachyzoites was significantly reduced when BeWo cells were treated with TGFB1 and Smad2 inhibitor, demonstrating that the higher infectivity by T. gondii in BeWo cells in the presence of TGFB1 was dependent on Smad2 activation. Thus, at least in BeWo trophoblast cells, TGFB1 triggers Smad2-dependent intracellular pathways and is significantly associated with increased parasite growth. In agreement with our data, several studies have shown Smad2 phosphorylation triggered by TGFB, but this was during the immune response in T cells [51] [52] [53] . The Smad2 phosphorylation induced by TGFB is essential for Th17 cell generation [51, 53] . IFNG production by CD8 þ T cells during acute and chronic feline immunodeficiency virus infection was downmodulated by T regulatory cells, and this mechanism of suppression was associated with Smad2 phosphorylation triggered by TGFB [52] . Also, it was previously shown that TGFB signaling can also operate in Smad-independent pathways [54, 55] , but future studies are necessary to investigate these alternative pathways in BeWo cells. Next, we investigated the role of the IL10/STAT3 and TGFB/Smad2 pathways in cytokine production. Down-modulation of TNFA and IL6 levels was detected in BeWo cells treated with IL10. These findings were confirmed in the presence of the STAT3 inhibitor (WP1066) where upregulation of TNFA was detected in cells treated with IL10 and WP1066, showing that the TNFA release in BeWo trophoblast cells is dependent on STAT3 down-modulation. However, this up-regulatory effect was not observed for IL6 in BeWo cells treated with STAT3 inhibitor, probably because this transcriptional factor is also involved in the induction of IL6 production. Therefore, in our experimental model, the increased T. gondii infection in BeWo cells under IL10 INTRACELLULAR PATHWAYS AND T. GONDII INFECTION treatment was associated with reduced levels of these cytokines, IL6 and TNFA, and this effect was dependent on STAT3 phosphorylation. We also demonstrated that TGFB1 down-modulated IL6 in BeWo cells and was dependent on Smad2 phosphorylation because up-regulation of IL6 was detected in cells treated with TGFB1 and Smad2 inhibitor. Subsequently, we hypothesized that the increased infectivity to T. gondii under TGFB1 or IL10 treatments was associated with IL6 or TNFA reduction. This hypothesis was strengthened because a decrease in the parasite proliferation in BeWo cells treated with TNFA and IL6 recombinant cytokines was verified in our experimental model. Higher T. gondii proliferation in BeWo trophoblast cells was observed during treatment with IL10 or TGFB1 because these cytokines are able to downmodulate IL6 and TNFA in a manner that is dependent on STAT3 and Smad2 activation, creating an environment of cytokine modulation able to favor or benefit the parasite growth. This study is the first to show it in a human trophoblast model.
Our previous studies demonstrated that BeWo cells produce IL10 and TGFB1 naturally [15, 18] , probably to avoid fetal rejection, which, at the same time, favors infection by many pathogens, such as T. gondii [15] . It is possible to hypothesize that these cytokines released by trophoblast cells (IL10 and TGFB1) in the maternal-fetal interface can induce some neighboring cells, such as monocytes, to change their cytokine profile and thus promote a milieu of mediators that favor the infection. This was found in a previous study that demonstrated an impaired immune response against bacterial stimuli in human monocytes (THP-1) cultured with trophoblast supernatant, especially reduced IL6 levels, showing the ability of trophoblast cells to modulate the immune response in cells found in the maternal-fetal interface [56] . Also, our previous study showed that the supernatant of BeWo cells induced increased IL10 and IL6 production in THP-1 cells [18] . Therefore, although trophoblast cells are not considered cells with innate or adaptive immunity, they are potentially able to modulate the immune response in the maternal-fetal interface. In this context, it is possible that IL10 and TGFB1 released by trophoblast cells trigger STAT3 and Smad2 in other cells of the maternal-fetal interface, modulating the cytokine profile and favoring the establishment of the infection. However, there are studies that demonstrate immune activation of trophoblast cells, including BeWo cells, as evidenced by the fact that many types of toll-like receptors are expressed and functional in these cells [57] . In this context, it is possible to assume that trophoblast cells are able to modulate the cytokine profile and influence the control of a T. gondii infection.
The role of TNFA in the immune response against T. gondii is well known [58] . Increased levels of TNFA were observed in infected women, and higher IL10 production was found to prevent an exacerbated immune response, showing the role of IL10 in down-modulating TNFA [59] . The release of TNFA was reduced by endogenous IL10 in mice infected by T. gondii, demonstrating a protective mechanism mediated by IL10 that prevents a strong immunopathology [60] . The biological activities of TNFA are mediated by two different receptors, TNFR1 and TNFR2. TNFR1 seems to be the main mediator of TNFA signaling, leading to proinflammatory response [61] . TNFR1 signaling results in the activation of IB kinase (IKK) and, consequently, the activation of nuclear kappa B (NFKB) factor in different physiological and pathological conditions, promoting the secretion of proinflammatory mediators [61, 62] . In addition, TNFR1 also triggers the extracellular signal-regulated kinase (ERK), the c-June Nterminal kinase (JNK) and the p38 mitogen-activated protein kinase (p38 MAPK) in response to TNFA [63] . These pathways can be activated in trophoblast cells because some previous studies demonstrated expression of TNFA and its receptors (both TNFR1 and TNFR2) in human trophoblast isolated from placenta [61] and also in BeWo cells [64] . Thus, when BeWo cells were treated with rTNFA, we speculated that this cytokine triggered NFKB or the MAPKs as described above, promoting the production of proinflammatory mediators that are able to control the parasite infection. However, in the presence of rIL10, down-modulation of TNFA was detected, and it was not possible to verify the paracrine activity of TNFA and its mediators during the infection. Previous studies demonstrated that IL10 down-regulated the activity of TNFA by increasing the release of soluble TNFR1 and TNFR2, reducing the surface expression of both receptors [65] . It may be that IL10 down-modulated TNFA activity in our present study by inducing increased release of soluble TNF receptors, avoiding the signaling of the cytokine. Villous trophoblast and BeWo cells are able to release the soluble forms of these receptors in order to protect against the cytotoxic effects of TNFA [64] . Overall, future investigations are necessary to verify these pathways and the production of proinflammatory mediators in BeWo cells stimulated with TNFA.
Like TNFA, several studies have demonstrated the protective effect of IL6 against T. gondii infection [18, 66, 67] , although not in trophoblast cells, and our study was the first to show this effect in a human trophoblast model. IL6 has important roles in the maternal-fetal interface that could explain its increased level in trophoblast cells [68] [69] [70] . Studies have shown that IL6 participates in the migration and invasion of trophoblasts into the endometrium [71] . Other studies have demonstrated high levels of production of IL6 by BeWo cells and its involvement in the endocrine properties of these cells [22, 72] . However, this cytokine should be at adequate concentrations at the maternal-fetal interface because high levels of IL6 are associated with preeclampsia and inflammatory processes in the amnion [73, 74] . Thus, it is plausible that TGFB1 and IL10 down-modulate IL6 release in order to control the level of this cytokine in BeWo cells, which in turn, promotes the increased proliferation of T. gondii, allowing dissemination of the infection in our model. Moreover, previous studies have demonstrated that IL6 triggers intracellular signaling pathways in a manner dependent on STAT1 and STAT3 [75] or ERK1/2 [76] . In our present study, the pathways triggered by IL6 in BeWo cells were not verified, but we detected reduced T. gondii proliferation in cells stimulated with rIL6. Therefore, it is possible to hypothesize that IL6 can activate STAT1 or ERK1/2 and promote the parasite control in BeWo trophoblast cells, while this situation becomes dampened when BeWo cells are stimulated with IL10 or TGFB1. Future studies are necessary to verify the signaling pathway triggered by IL6 in BeWo cells.
When we investigated the role of IFNG in the T. gondii proliferation, we observed that concentrations lower than 50 ng/ml were unable to control the number of tachyzoites. Interestingly, concentrations higher than 50 ng/ml promoted increased infectivity in BeWo cells. Our previous studies have already shown that IFNG is not able to control T. gondii infection [14] or can simply favor the infection in BeWo cells [15] , which contrasts with several studies that have demonstrated the effect of this cytokine against the parasite in other cell types [7] [8] [9] [10] . To understand the intracellular mechanism triggered by IFNG in BeWo cells, which could clarify the role of this cytokine at the maternal-fetal interface, we investigated the STAT1-dependent intracellular signaling pathway. STAT1 phosphorylation was detected in BeWo cells treated only with BARBOSA ET AL. 20 ng/ml IFNG. We did not verify any STAT1 activation with 100 ng/ml IFNG. We therefore concluded that higher T. gondii proliferation is present when there is no STAT1 phosphorylation. This was confirmed when we used a STAT1 inhibitor in the presence of 20 ng/ml IFNG, demonstrating that STAT1 activation is associated with control of the parasite. To clarify the dose-dependent effect of IFNG on the control of T. gondii infection, we measured cytokine release in cells treated with 20 or 100 ng/ml IFNG.
BeWo cells treated with 20 ng/ml IFNG increased IL6 and IL17A production when infected or not with T. gondii, and this was confirmed by blocking STAT1 (Fludarabine), showing that the cytokines released (IL6 and IL17A) are dependent on STAT1 activation. IFNG in low concentration was the only cytokine able to trigger IL17A production in BeWo cells, regardless of the presence or absence of infection. This means that, at least in BeWo cells, STAT1 is the major pathway involved in the release of this cytokine, demonstrating the role of IL17A in the control of T. gondii infection, as observed with IL6. Additionally, BeWo cells treated with IFNG and Fludarabine showed up-regulation of IL10, even though IL10 levels were not reduced in the absence of the inhibitor. Although IFNG triggered STAT1 phosphorylation when added to cells at a concentration of 20 ng/ml, this cytokine was unable to control T. gondii infection, even with increased IL6 and IL17A secretion. On the other hand, BeWo cells treated with100 ng/ml IFNG significantly reduced both IL6 and TNFA. The results suggest that BeWo cells demonstrated increased T. gondii infection in the presence of IFNG in high concentrations because IL6 and TNFA were down-modulated, creating a microenvironment favoring parasite proliferation, as observed during the treatments with IL10 and TGFB1.
Our present findings demonstrated that 20 ng/ml IFNG was not able to control T. gondii infection even in the presence of STAT1 phosphorylation and high IL6 levels in BeWo cells. Previous studies have shown that trophoblast cell lines such as Jar and JEG have low levels of STAT1 phosphorylation in comparison to some other cell lineages, including HeLa, where IFNG triggered higher STAT1 phosphorylation and interferon regulator factor 1 (IRF1) expression in comparison to trophoblasts [31] . Based in these evidences, we can hypothesize that BeWo cells might present low STAT1 activation in the presence of 20 ng/ml IFNG, which may not be sufficient to control the parasite. Alternatively, it has been demonstrated that 20 ng/ml IFNG promoted increased intercellular adhesion molecule 1 (ICAM1) expression in BeWo cells [77] . Also, T. gondii was able to use ICAM1 to infect human intestinal cells as well as BeWo cells by binding the microneme protein 2 of the parasite (MIC2) to ICAM1 of the host cells, demonstrating a key role of ICAM1 in the spreading of T. gondii through biological barriers, including the maternal-fetal interface [78] . Based on this evidence, we can speculate that exposure of BeWo cells to low levels of IFNG, even with STAT1 phosphorylation and IL6 production, up-regulates ICAM1, favoring invasion of the parasite and thus failing to control the infection. Interestingly, our previous study demonstrated that IFNG increased the macrophage migration inhibitory factor (MIF) expression in human villous explants from the first trimester, which, in turn, induced higher ICAM1 expression, especially in the syncytiotrophoblast [79] . These data reinforce our hypothesis that 20 ng/ml IFNG does not control T. gondii infection in human trophoblast cells because this cytokine is an important regulator of ICAM1.
Based in our findings and all the discussion about the role of IFNG in trophoblast cells infected by T. gondii, it is ineluctable to ask which concentration reproduces the physiological condition in the maternal-fetal interface. A previous study showed almost no IFNG secretion in human trophoblast from the first trimester, while the decidual immune cells were the only cells types that produced this cytokine [80] . Then, the local immune cells are the major source of IFNG in the maternal-fetal interface because the decidual natural killer cells, and consequently the trophoblast cells, are stimulated by IFNG in a paracrine manner. Decidual natural killer cells cocultured with trophoblast produce from 20 to 30 ng/ml IFNG, and this production increases significantly when these cells are infected by T. gondii (;80 ng/ml) [81] . Therefore, the IFNG concentrations used in our present study are similar to those found during in vivo conditions. It is difficult to ascertain precisely the function of IFNG at the maternal-fetal interface, that is, proinflammatory or anti-inflammatory, because at least in BeWo cells, this cytokine was unable to control the parasite's growth, considering that our data demonstrate that IFNG has different activities, depending on its concentration.
Altogether, our results demonstrate that BeWo cells present high infectivity to T. gondii when treated with IL10, TGFB1, and IFNG because these cytokines differentially trigger, in a dependent manner, specific intracellular signaling pathways and, consequently, create a milieu with other cytokines, especially down-modulation of IL6 and TNFA, that dampens an immune response against T. gondii and allows its intracellular proliferation. Our findings open up new avenues to understand the effector mechanisms triggered by these key cytokines in a human trophoblast model (BeWo cells) under T. gondii infection, helping to elucidate the mechanisms involved in the vertical transmission of this parasite.
